In accordance, TXNIP inhibitor SBI477 counteracted imatinib mediated suppression of cell survival and glucose uptake and induction of apoptosis in primary CML cells (Fig. 7D–F). This evidence concerns the gene TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive.